Inclusion Criteria:

          -  Histologically or cytologically confirmed solid tumors with evidence of metastatic or
             locally advanced unresected disease that is incurable.

          -  Patients with NSCLC or other solid tumors who have failed prior standard first-line
             treatment. Patients must have progressed on or be intolerant to therapies that are
             known to provide clinical benefit. There is no limit to the number of prior treatment
             regimens.

          -  Availability of archival or a fresh tumor tissue sample.

          -  Measurable disease as defined by RECIST version 1.1 by radiologic methods.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Life expectancy ≥ 12 weeks, as per Investigator.

          -  Adequate organ function:

               -  Absolute neutrophil count (ANC) ≥1.5 X 109/L

               -  Hemoglobin ≥9 g/dL

               -  Platelets ≥100 x 109/L

               -  Corrected total serum calcium within normal ranges

               -  Serum magnesium within normal ranges (or corrected with supplements)

               -  Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤3 x upper limit
                  of normal (ULN) and total bilirubin ≤1.5 x ULN (patients with Gilbert's syndrome
                  are eligible if conjugated bilirubin value is within normal limits); in cases of
                  liver involvement, ALT/AST ≤5 x ULN and total bilirubin ≤2 x ULN will be allowed

               -  Serum creatinine ≤1.5 x ULN or creatinine clearance ≥50 mL/min calculated
                  according to the Cockcroft and Gault formula or MDRD formula for patients aged
                  >65 years

               -  Serum albumin >3.3 g/dL

        Exclusion Criteria:

          -  Central nervous system metastases that are untreated or symptomatic, or require
             radiation, surgery, or continued steroid therapy (> 10 mg prednisone or equivalent) to
             control symptoms within 14 days of study entry.

          -  Known leptomeningeal involvement.

          -  Participation in another clinical study or treatment with any investigational drug
             within 4 weeks prior to study entry.

          -  Prior treatment with a bispecific EGFR-c-MET antibody.

          -  Systemic anticancer therapy or immunotherapy within 4 weeks or 5 half-lives, whichever
             is shorter, of the first dose of study drug. For cytotoxic agents that have major
             delayed toxicity (e.g., mitomycin C, nitrosoureas), a washout period of 6 weeks is
             required.

          -  Major surgery or radiotherapy within 3 weeks of the first dose of study drug.

          -  Persistent grade >1 clinically significant toxicities related to prior antineoplastic
             therapies (except for alopecia); stable sensory neuropathy ≤ grade 2 NCI-CTCAE v5.0
             and hypothyroidism ≤ grade 2 which is stable on hormone replacement are allowed.

          -  History of hypersensitivity reaction or any toxicity attributed to human proteins or
             any of the excipients that warranted permanent cessation of these agents.

          -  History of clinically significant cardiovascular disease including, but not limited
             to:

               -  Diagnosis of deep vein thrombosis or pulmonary embolism within 1 month prior to
                  first dose of study drug, or any of the following within 6 months prior to the
                  first dose of study drug: myocardial infarction, unstable angina, stroke,
                  transient ischemic attack, coronary/peripheral artery bypass graft, or any acute
                  coronary syndrome.

               -  Prolonged QT interval > 480 msec or clinically significant cardiac arrythmia or
                  electrophysiologic disease (i.e., placement of implantable cardioverter
                  defibrillator or atrial fibrillation with uncontrolled rate). Patients with
                  cardiac pacemakers who are clinically stable are eligible.

               -  Uncontrolled (persistent) arterial hypertension: systolic blood pressure > 180 mm
                  Hg and/or diastolic blood pressure > 100 mm Hg.

               -  Congestive heart failure (CHF) defined as New York Heart Association (NYHA) class
                  III-IV or hospitalization for CHF within 6 months of the first dose of study
                  drug.

               -  Clinically significant pericardial effusion.

               -  Myocarditis.

          -  History of interstitial lung disease including drug-induced interstitial lung disease,
             radiation pneumonitis that requires treatment with prolonged steroids or other immune
             suppressive agents within 1 year.

          -  Previous or concurrent malignancy, excluding non-basal cell carcinomas of skin or
             carcinoma in situ of the uterine cervix, unless the tumor was treated with curative or
             palliative intent and in the opinion of the Investigator, with Sponsor agreement, the
             previous or concurrent malignancy condition does not affect the assessment of safety
             and efficacy of the study drug.

          -  Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen
             therapy.

          -  Current serious illness or medical conditions including, but not limited to
             uncontrolled active infection, clinically significant pulmonary, metabolic or
             psychiatric disorders

          -  Active Hepatitis B infection (HBsAg positive) without receiving antiviral treatment.

          -  Positive test for Hepatitis C ribonucleic acid (HCV RNA);

          -  Known history of HIV (HIV 1/2 antibodies).